 |
32 Diseases |  |
6 Trials |
|
6 Trials |  |
56 News |  |
- | Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
New trial: Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=50, Recruiting, Sponsor: Parc Taul
- | Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Flucelvax (influenza virus trivalent vaccine) / CSL Behring, Influvac (influenza virus surface antigens) / Abbott, Viatris
Journal: Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024. (Pubmed Central) - Mar 13, 2024
Key changes for the 2023-2024 season include: 1) incorporation of updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19); 2) new recommendations for Flucelvax
- || Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
Review, Journal: Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity. (Pubmed Central) - Dec 17, 2023
ECDC recommends that EU Member States implement action plans and policies aimed at reaching 75% coverage in at-risk groups and healthcare workers. Even so, vaccine coverage is still far from recommended.
- Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
Immune Responses after One Versus Two Influenza A/B Vaccinations in Patients with Multiple Myeloma (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6189;
Current therapy, uncontrolled MM, present immunoparesis and low CD19 + B-cell counts were associated with inferior response rates. Those patients exceptionally benefitting from a boost vaccination were characterized by recent autoHSCT.
- | VXS-1222 / Vaxxas
Trial completion: Phase I clinical study to evaluate the safety and tolerability of Quadrivalent Influenza Vaccine (QIV) delivered intradermally by a high-density micro-array patch (HD MAP), compared to intramuscular Influvac (EUDRACT) - Sep 13, 2023
P=N/A, N=150, Completed, Sponsor: Vaxxas Pty Ltd
Those patients exceptionally benefitting from a boost vaccination were characterized by recent autoHSCT. Recruiting --> Completed
- | Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
Journal: Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines. (Pubmed Central) - Sep 12, 2023
Geometric mean titers in the coadministration group were estimated to be 0.84 (95% CI, 0.69-1.04) times lower than in the COVID-19 vaccine-alone group. In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines.
- | VXS-1222 / Vaxxas
Trial initiation date: Phase I clinical study to evaluate the safety and tolerability of Quadrivalent Influenza Vaccine (QIV) delivered intradermally by a high-density micro-array patch (HD MAP), compared to intramuscular Influvac (EUDRACT) - Sep 1, 2023
P=N/A, N=150, Recruiting, Sponsor: Vaxxas Pty Ltd
In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines. Initiation date: Nov 2000 --> Nov 2022
- Subsequent vaccinations in VITT patients other than SARS-CoV2 vaccination (#43) (foyer) - Feb 8, 2023 - Abstract #GTH2023GTH_324;
Introduction Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare, but severe side effect after vaccination with adenovirus vector-based vaccines (ChAdOx1 nCoV-19, AstraZeneca and Ad26.COV2.S, Johnson & Johnson/Janssen) in which platelet activating anti-platelet factor 4 (PF4) antibodies cause thrombocytopenia and thrombosis at unusual sites...During the follow-up period, eight vaccinations other than against Covid-19 were reported: six vaccinations against influenza (three Influvac, two Vaxigrip Tetra, one Influsplit Tetra) and two consecutive vaccinations against tick-borne encephalitis (TBE) in one patient...Conclusion Similar to observations after consecutive mRNA vaccinations against Covid-19 in VITT patients, vaccinations against influenza and TBE very unlikely to reactivate platelet-activating anti-PF4-antibodies. Further follow up of the VITT patient cohort is performed to detect any new safety signal related to recurrence of VITT.
- | Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
Journal: Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. (Pubmed Central) - Jan 6, 2023
Further follow up of the VITT patient cohort is performed to detect any new safety signal related to recurrence of VITT. Recent influenza vaccination is associated with a significant reduction in the risk of SARS-CoV-2 infection and COVID-19 severity.
- | Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
Journal: Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons. (Pubmed Central) - Dec 16, 2022
The EPSS set up for Influvac® and Influvac® Tetra proved a robust and effective methodology to comply with the objectives of EMÁ's guidance on enhanced safety surveillance of seasonal influenza vaccines. Safety data from seven consecutive seasons confirmed the favourable safety profile of both vaccines.
- Influvac (influenza virus surface antigens) / Abbott
Results from the Enhanced Passive Safety Surveillance for the influenza vaccine Influvac Tetra in Germany during 2021/2022 vaccination season () - Sep 28, 2022 - Abstract #OPTIONSXI2022OPTIONS_XI_486;
- Influvac (influenza virus surface antigens) / Abbott
A pilot study on the effectiveness of Influenza Vaccination to prevent relapse of steroid sensitive nephrotic syndrome in children. (Poster Area - Exhibition Hall E) - Sep 20, 2022 - Abstract #IPNA2022IPNA_51;
Objectives:To study the effect of influenza vaccination in children with Steroid Sensitive Nephrotic Syndrome by comparing the frequency of viral Upper Respiratory Tract Infections (URI) and associated relapses from historic controls.Materials and Trivalent, inactivated Influenza vaccine (Influvac 2019/2020) was given to children with steroid sensitive nephrotic syndrome in 2019... There seems to be a significant decrease in all-cause URI and relapses in steroid sensitive nephrotic children who are vaccinated with flu vaccine. Further trials in larger cohorts are required to confirm the beneficial effect of this recommended vaccination.
- || OVX836 / Osivax, National Institute of Allergy and Infectious Diseases
Clinical, P2a data, Journal: Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine. (Pubmed Central) - Apr 26, 2022
P2a
In conclusion, these results encourage further clinical evaluation of OVX836 in order to confirm the signal of efficacy on ILIs and/or laboratory-confirmed influenza cases. NCT04192500 (https://clinicaltrials.gov/ct2/show/study/NCT04192500).
- ||| Influvac (influenza virus surface antigens) / Abbott
Clinical, P3 data, Journal: Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study. (Pubmed Central) - Apr 19, 2022
Influvac® Tetra elicited an adequate immune response with a favorable safety profile which was comparable with the reference vaccine. (Clinical trial registry number: CTRI/2018/02/012222).
- | Influvac (influenza virus surface antigens) / Abbott
Preclinical, Journal: Exposure to Deoxynivalenol During Pregnancy and Lactation Enhances Food Allergy and Reduces Vaccine Responsiveness in the Offspring in a Mouse Model. (Pubmed Central) - Feb 16, 2022
Male offspring were injected with Influvac vaccine...In conclusion, early life dietary exposure to DON can adversely influence immune development in the offspring. Consequently, the immune system of the offspring may be skewed towards an imbalanced state, resulting in an increased allergic immune response to food allergens and a decreased immune response to vaccination against influenza virus in these models.
- | Influvac (influenza virus surface antigens) / Abbott, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: B cell depletion impairs vaccination-induced CD8 T cell responses in a type I interferon-dependent manner. (Pubmed Central) - Dec 16, 2021
Thus, B cell depletion causes a deficiency of de novo antibody responses and affects the efficacy of cellular response including cytotoxic T cells. The choice of the appropriate vaccine to vaccinate B cell-depleted patients has to be re-evaluated in order to efficiently induce protective CD8 T cell responses.
- | Fluzone QIV HD (quadrivalent inactivated influenza vaccine) / Evotec, Sanofi, Influvac (influenza virus surface antigens) / Abbott
Journal: Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2021-2022. (Pubmed Central) - Oct 20, 2021
NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to anyone six months of age and older who does not have contraindications to the vaccine. Vaccination should be offered as a priority to people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk of complications, and others as indicated.
- || Influvac (influenza virus surface antigens) / Abbott
Dankeschön für die Antwort!! Kann man sagen, dass die Subunitimpfstoffe (Influvac, Flucelvax) besser verträglich sind als die Spaltimpfstoffe (Vaxigrip, Fluarix), weil reiner, oder ist das eine laienhaft falsche Schlussfolgerung? (Twitter) - Oct 15, 2021
- | Journal: Influenza vaccine for 2021-2022. (Pubmed Central) - Oct 7, 2021
Vaccination should be offered as a priority to people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk of complications, and others as indicated. No abstract available
- ||| Influvac (influenza virus surface antigens) / Abbott
👍 Excellent synthesis by @DLBHATTMD ➡️ What will happen at #ESCCongress next week? I'll add to the list the WHF largest worldwide Covid and CV disease registry ✅ Eyes open for colchicine, Vascepa, influVac, Tica, and Empa (Twitter) - Aug 20, 2021
- || zorecimeran (CV07050101) / CureVac
Enrollment change, Trial withdrawal: CV-NCOV-011: COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (clinicaltrials.gov) - Aug 18, 2021
P3, N=0, Withdrawn, Sponsor: Bayer
No abstract available N=1000 --> 0 | Not yet recruiting --> Withdrawn
- ||||| zorecimeran (CV07050101) / CureVac
Trial initiation date: CV-NCOV-011: COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (clinicaltrials.gov) - Jun 8, 2021
P3, N=1000, Not yet recruiting, Sponsor: Bayer
N=1000 --> 0 | Not yet recruiting --> Withdrawn Initiation date: May 2021 --> Oct 2021
- |||||||||| zorecimeran (CV07050101) / CureVac
New P3 trial: CV-NCOV-011: COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (clinicaltrials.gov) - Apr 19, 2021
P3, N=1000, Not yet recruiting, Sponsor: Bayer
- |||| OVX836 / Osivax, National Institute of Allergy and Infectious Diseases
Trial completion, Trial completion date: Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years (clinicaltrials.gov) - Oct 28, 2020
P2a, N=300, Completed, Sponsor: Osivax S.A.S
Initiation date: May 2021 --> Oct 2021 Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Sep 2020
- || Influvac (influenza virus surface antigens) / Abbott
U pravu ste ima i Influvac tetra😊, ali je ona za starije od 18 godina, trovalentna ja za uzrast od 6 meseci, pa na dalje (Twitter) - Oct 24, 2020
- | Influvac (influenza virus surface antigens) / Abbott
Kako pretrazujete? Najavljivali su i po medijima i prilicno sam siguran da sam i procitao u domu zdravlja kada sam primao, da je u pitanju influvac tetra. (Twitter) - Oct 24, 2020
- || Influvac (influenza virus surface antigens) / Abbott
#influvac, proizvođač @AbbottNews 👇 3 soja, daje se od 6 meseci na dalje (Twitter) - Oct 24, 2020
- | Influvac (influenza virus surface antigens) / Abbott
new yearly strain of Swine flu vaccine is available with quadri strains by both @sanofi and @abbott so please get urself vaccinated. everyone 6 months above of age can get it. #preventionisbetterthancure #swineflu #fluquadri #influvactetra (Twitter) - Sep 21, 2020
- ||||||| Influvac (influenza virus surface antigens) / Abbott, Viatris
Trial completion: Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (clinicaltrials.gov) - Jun 29, 2020
P3, N=1540, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Sep 2020 Recruiting --> Completed
- ||||| Influvac (influenza virus surface antigens) / Abbott, Viatris
Trial initiation date: Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (clinicaltrials.gov) - Jun 16, 2020
P3, N=1540, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Initiation date: Oct 2019 --> Apr 2019
- ||| OVX836 / Osivax, National Institute of Allergy and Infectious Diseases
Enrollment closed: Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years (clinicaltrials.gov) - Apr 3, 2020
P2a, N=300, Active, not recruiting, Sponsor: Osivax S.A.S
Initiation date: Oct 2019 --> Apr 2019 Recruiting --> Active, not recruiting
- | Journal: Influenza vaccine for 2019-2020. (Pubmed Central) - Dec 22, 2019
Recruiting --> Active, not recruiting No abstract available
- |||| OVX836 / Osivax, National Institute of Allergy and Infectious Diseases
Enrollment open: Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years (clinicaltrials.gov) - Dec 12, 2019
P2a, N=300, Recruiting, Sponsor: Osivax S.A.S
No abstract available Not yet recruiting --> Recruiting
- ||||| OVX836 / Osivax, National Institute of Allergy and Infectious Diseases
New P2a trial: Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years (clinicaltrials.gov) - Dec 9, 2019
P2a, N=300, Not yet recruiting, Sponsor: Osivax S.A.S
- |||||| Influvac (influenza virus surface antigens) / Abbott, Viatris
Enrollment open: Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (clinicaltrials.gov) - Oct 28, 2019
P3, N=1540, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Influvac (influenza virus surface antigens) / Abbott, Viatris
New trial: Immune Response to Influenza Vaccine in ESRD Patients (clinicaltrials.gov) - Oct 9, 2019
P=N/A, N=60, Completed, Sponsor: Mahidol University
- | Influvac (influenza virus surface antigens) / Abbott, Viatris
New P3 trial: Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (clinicaltrials.gov) - Jul 17, 2019
P3, N=1540, Not yet recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- | Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Influvac (influenza virus surface antigens) / Abbott, Viatris
New trial: Response of Immune System to Flu Vaccination in PHTS (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=30, Not yet recruiting, Sponsor: Radboud University
- | Influvac (influenza virus surface antigens) / Abbott
New trial: Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial (clinicaltrials.gov) - Jan 16, 2018
P=N/A, N=240, Recruiting, Sponsor: Tan Tock Seng Hospital
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change, Trial termination, Trial primary completion date: CLLIFVAC: Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients (clinicaltrials.gov) - Apr 12, 2017
P2, N=24, Terminated, Sponsor: The Royal Bournemouth Hospital
Not yet recruiting --> Recruiting N=102 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Recruitment issues
- ||||||| Influvac (influenza virus surface antigens) / Abbott
Trial completion, Enrollment closed: Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season (clinicaltrials.gov) - Apr 5, 2015
P3, N=120, Completed, Sponsor: Abbott
N=102 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Recruitment issues Active, not recruiting --> Completed
- |||||||||| Influvac (influenza virus surface antigens) / Abbott
New P3 trial: Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season (clinicaltrials.gov) - Mar 7, 2015
P3, N=120, Recruiting, Sponsor: Abbott
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Rituxivac: Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=98, Completed, Sponsor: St. Antonius Hospital
Active, not recruiting --> Completed N=160 --> 98
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituxivac: Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=98, Completed, Sponsor: St. Antonius Hospital
N=160 --> 98 Recruiting --> Completed
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment closed: CLLIFVAC: Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients (clinicaltrials.gov) - Nov 28, 2012
P2, N=102, Active, not recruiting, Sponsor: The Royal Bournemouth Hospital
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Influvac (influenza virus surface antigens) / Abbott
New P3 trial: Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season (clinicaltrials.gov) - Jul 2, 2012
P3, N=120, Completed, Sponsor: Abbott Biologicals